X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8407) 8407
Book Chapter (42) 42
Dissertation (26) 26
Publication (15) 15
Book / eBook (8) 8
Conference Proceeding (7) 7
Newspaper Article (3) 3
Web Resource (3) 3
Government Document (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
biochemistry & molecular biology (2533) 2533
subtilisin (2382) 2382
animals (2332) 2332
humans (2034) 2034
amino acid sequence (1768) 1768
subtilisins - metabolism (1714) 1714
molecular sequence data (1561) 1561
proteins (1219) 1219
kinetics (987) 987
enzymes (974) 974
subtilisins - genetics (933) 933
biotechnology & applied microbiology (800) 800
subtilisins - chemistry (772) 772
furin (725) 725
proprotein convertases (682) 682
expression (681) 681
binding sites (669) 669
hydrolysis (661) 661
protein conformation (657) 657
substrate specificity (651) 651
proteases (642) 642
base sequence (632) 632
mice (622) 622
cholesterol (608) 608
male (603) 603
hydrogen-ion concentration (576) 576
research (572) 572
models, molecular (562) 562
subtilisins (554) 554
analysis (552) 552
peptides (548) 548
serine endopeptidases - metabolism (539) 539
female (523) 523
purification (520) 520
biophysics (516) 516
protease (515) 515
microbiology (510) 510
subtilisin/kexin type 9 (507) 507
mutation (505) 505
identification (458) 458
protein (452) 452
cell biology (450) 450
molecular weight (448) 448
food science & technology (419) 419
protein binding (419) 419
protein processing, post-translational (417) 417
cloning, molecular (412) 412
crystal-structure (412) 412
serine endopeptidases - genetics (412) 412
rats (411) 411
catalysis (406) 406
gene (404) 404
lipids (386) 386
kexin (385) 385
subtilisins - antagonists & inhibitors (384) 384
hypercholesterolemia (382) 382
cell line (348) 348
electrophoresis, polyacrylamide gel (348) 348
research article (348) 348
pcsk9 (347) 347
escherichia-coli (343) 343
gene expression (342) 342
sequence homology, amino acid (342) 342
enzyme stability (333) 333
recombinant proteins - metabolism (331) 331
temperature (331) 331
lipoproteins (329) 329
mutagenesis, site-directed (329) 329
protein precursors - metabolism (327) 327
trypsin (322) 322
statins (318) 318
proprotein convertase subtilisin/kexin type 9 (312) 312
cardiac & cardiovascular systems (311) 311
monoclonal-antibody (309) 309
sequence (306) 306
multidisciplinary sciences (302) 302
atherosclerosis (297) 297
proprotein convertase 9 (297) 297
structure-activity relationship (294) 294
proprotein convertase 2 (293) 293
proteolysis (293) 293
amino acids (291) 291
chemistry (290) 290
subtilisin carlsberg (289) 289
pharmacology & pharmacy (287) 287
serine endopeptidases - chemistry (285) 285
middle aged (284) 284
cardiovascular disease (281) 281
protein folding (281) 281
low density lipoproteins (280) 280
subtilisin - metabolism (279) 279
chymotrypsin (277) 277
cattle (274) 274
familial hypercholesterolemia (273) 273
physiological aspects (272) 272
cloning (271) 271
life sciences (270) 270
stability (270) 270
saccharomyces cerevisiae proteins (265) 265
bacillus - enzymology (259) 259
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8260) 8260
Japanese (201) 201
Russian (126) 126
German (45) 45
Chinese (28) 28
Spanish (14) 14
French (11) 11
Korean (11) 11
Portuguese (9) 9
Polish (6) 6
Czech (2) 2
Hungarian (2) 2
Croatian (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal of Lipid Research, ISSN 0022-2275, 11/2014, Volume 55, Issue 11, pp. 2370 - 2379
LDL cholesterol (LDL-C) contributes to coronary heart disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases LDL-C by inhibiting LDL-C... 
Anti-proprotein convertase subtilisin/kexin type 9 antibody | Proprotein convertase subtilisin/kexin type 9 | Low density lipoprotein receptor | Apolipoprotein E | proprotein convertase subtilisin/kexin type 9 | FAMILIAL HYPERCHOLESTEROLEMIA | ESTER TRANSFER PROTEIN | AUTOSOMAL-DOMINANT HYPERCHOLESTEROLEMIA | BIOCHEMISTRY & MOLECULAR BIOLOGY | SUBTILISIN/KEXIN TYPE 9 | anti-proprotein convertase subtilisin/kexin type 9 antibody | low density lipoprotein receptor | MONOCLONAL-ANTIBODY | KNOCKOUT MICE LACKING | REDUCES ATHEROSCLEROSIS | LOWERING PLASMA-CHOLESTEROL | apolipoprotein E | DENSITY-LIPOPROTEIN RECEPTOR | TRANSGENIC MICE | Apolipoproteins E - deficiency | Atherosclerosis - genetics | Cholesterol - blood | Humans | Proprotein Convertases - genetics | Atherosclerosis - enzymology | Liver - drug effects | Serine Endopeptidases - genetics | Serine Endopeptidases - immunology | Antibodies - immunology | Female | Serine Endopeptidases - deficiency | Liver - metabolism | Proprotein Convertases - metabolism | Receptors, LDL - metabolism | Gene Knockout Techniques | Proprotein Convertases - deficiency | Atherosclerosis - metabolism | Proprotein Convertases - immunology | Atherosclerosis - blood | Animals | Mice | Serine Endopeptidases - metabolism | Cholesterol Ester Transfer Proteins - metabolism | Proprotein Convertase 9 | kexin type 9 antibody | kexin type 9 | proprotein convertase subtilisin | anti-proprotein convertase subtilisin
Journal Article
PLoS ONE, ISSN 1932-6203, 03/2015, Volume 10, Issue 3, p. e0120508
Journal Article
Journal of lipid research, ISSN 1539-7262, 2016, Volume 57, Issue 6, pp. 1086 - 1096
Journal Article
Journal Article
Journal of Lipid Research, ISSN 0022-2275, 2017, Volume 58, Issue 10, pp. 2008 - 2016
An elevated level of lipoprotein (a) [Lp(a)] is a risk factor for CVD. Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9, is... 
Drug therapy/hypolipid-emic drugs | Lipoproteins | Genetic variability | Apolipoprotein (a) | Hypercholesterolemic | Low density lipoprotein cholesterol reduction | Proprotein convertase subtilisin/kexin type 9 | Familial hypercholesterolemia | Monoclonal antibody | Apolipoproteins | Lipoprotein (a) | Clinical studies | proprotein convertase subtilisin/kexin type 9 | apolipoproteins | MYOCARDIAL-INFARCTION | BIOCHEMISTRY & MOLECULAR BIOLOGY | hypercholesterolemic | PLASMA LIPOPROTEIN(A) | SUBTILISIN/KEXIN TYPE 9 | MONOCLONAL-ANTIBODY | drug therapy/hypolipidemic drugs | lipoprotein (a) | genetic variability | LDL CHOLESTEROL | DENSITY-LIPOPROTEIN CHOLESTEROL | CARDIOVASCULAR RISK-FACTOR | APOLIPOPROTEIN(A) ISOFORMS | familial hypercholesterolemia | HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | PCSK9 INHIBITION | apolipoprotein (a) | clinical studies | monoclonal antibody | lipoproteins | low density lipoprotein cholesterol reduction | Gene Expression Regulation - drug effects | Antibodies, Monoclonal, Humanized | Protease Inhibitors - pharmacology | Phenotype | Protein Isoforms - metabolism | Proprotein Convertase 9 - antagonists & inhibitors | Protein Isoforms - chemistry | Antibodies, Monoclonal - pharmacology | Humans | Apoprotein(a) - metabolism | Apoprotein(a) - chemistry | Lipoproteins (low density) | Hypercholesterolemia | Kexin | Alleles | Clinical trials | Monoclonal antibodies | Dominance | Subtilisin | Gene polymorphism | Low density lipoprotein | Cholesterol | kexin type 9 | drug therapy | proprotein convertase subtilisin | hypolipidemic drugs
Journal Article
Biochemical Journal, ISSN 0264-6021, 05/2009, Volume 419, Issue 3, pp. 577 - 584
PCSK9 (proprotein convertase subtilisin/kexin type 9) promotes degradation of the LDLR [LDL (low-density lipoprotein) receptor] through an as-yet-undefined... 
Surface plasmon resonance | Protein-protein interaction | Low-density lipoprotein receptor | Proprotein convertase subtilisin/kexin type 9 (PCSK9) | Antibody-mediated disruption | Cholesterol | FAMILIAL HYPERCHOLESTEROLEMIA | low-density lipoprotein receptor | LDL RECEPTOR | BIOCHEMISTRY & MOLECULAR BIOLOGY | antibody-mediated disruption | SECRETED PCSK9 | MUTANTS | PLASMA-CHOLESTEROL | GENE | surface plasmon resonance | cholesterol | DEGRADATION | protein-protein interaction | MICE | MUTATIONS | EXPRESSION | proprotein convertase subtilisin/kexin type 9 (PCSK9) | Cell Line | Reproducibility of Results | Humans | Insecta | Extracellular Space - drug effects | Models, Molecular | Receptors, LDL - metabolism | Mutant Proteins - metabolism | Epitopes | Antibodies - pharmacology | Extracellular Space - metabolism | Animals | Protein Binding - drug effects | Cholesterol, LDL - metabolism | Serine Endopeptidases - metabolism | Kinetics | Proprotein Convertases | Serine Endopeptidases - isolation & purification | Proprotein Convertase 9 | kexin type 9 | proprotein convertase subtilisin | BODIPY®, boron dipyrromethene (4,4-difluoro-4-bora-3a,4a-diaza-s-indacene | LDLc, LDL-cholesterol | FBS, fetal bovine serum | protein–protein interaction | kexin type 9 (PCSK9) | LDLR, LDL receptor | CHRD, cysteine | histidine-rich domain | MOI, multiplicity of infection | PCSK9, proprotein convertase subtilisin | RU, resonance units | HEK-F cells, Freestyle™ suspension human embryonic kidney cells | aa, amino acids | EGF-A, epidermal growth factor-like repeat A | LDL, low-density lipoprotein | SPR, surface plasmon resonance | IL1Ra, interleukin-1 receptor antagonist
Journal Article